STOCK TITAN

AKANDA CORP Stock Price, News & Analysis

AKAN Nasdaq

Welcome to our dedicated page for AKANDA news (Ticker: AKAN), a resource for investors and traders seeking the latest updates and insights on AKANDA stock.

Akanda Corp (AKAN) delivers medical cannabis solutions through regulated cultivation and innovative technology integration. This news hub provides investors and stakeholders with essential updates on the company's operations across three core segments: EU-GMP certified cannabis production, UK distribution via CanMart, and corporate strategy implementation.

Access timely press releases covering earnings reports, regulatory compliance milestones, partnership announcements, and technological advancements including blockchain supply chain initiatives and AI-driven operational improvements. Our curated collection ensures transparent tracking of AKAN's progress in pharmaceutical-grade cannabis production and international market expansion.

Bookmark this page for verified updates on cultivation facility developments, distribution network growth, and corporate governance changes. All content undergoes rigorous verification to maintain compliance with financial disclosure standards and medical cannabis regulations.

Rhea-AI Summary

Akanda, an international medical cannabis company trading on NASDAQ under the symbol AKAN, has closed its registered direct offering. The offering involved the sale of 2,491,381 common shares at $0.1031 per share and 21,756,922 pre-funded warrants at $0.103 per share. The warrants are immediately exercisable at $0.0001 per share. Univest Securities acted as the exclusive financial advisor. Gross proceeds were approximately $2.5 million, before deducting fees and expenses. Funds will be used for capital expenditures, working capital, corporate purposes, debt repayment, and acquisitions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.08%
Tags
-
Rhea-AI Summary

Akanda Corp. (NASDAQ: AKAN), a medical cannabis company, announced a securities purchase agreement with an accredited investor. The investor will acquire 2,491,381 common shares at $0.1031 each and 21,756,922 pre-funded warrants at $0.103 per share. The warrants are immediately exercisable at $0.0001 per share. The gross proceeds are estimated at $2.5 million, which Akanda will use for working capital and corporate expenses. The offering, expected to close around May 17, 2024, is made under Nasdaq rules and involves Univest Securities as the financial advisor. The securities are registered under an effective shelf registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.08%
Tags
-
Rhea-AI Summary

Akanda Corp. (NASDAQ: AKAN) received a deficiency notification from Nasdaq on May 14, 2024, for not meeting the minimum stockholders' equity requirement of $2.5 million.

As per their Form 20-F for the fiscal year ending December 31, 2023, Akanda's stockholders' equity was reported at ($3,828,892).

The company has until June 28, 2024, to submit a compliance plan. If accepted, Nasdaq may grant an extension of up to 180 days. Akanda plans to submit a comprehensive plan within this timeframe.

Meanwhile, their Nasdaq listing remains unaffected, and shares continue to trade under the symbol 'AKAN'.

Katie Field, interim CEO, affirmed that immediate steps are being taken to address the issue and regain compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.88%
Tags
none
Rhea-AI Summary

Akanda Corp (NASDAQ: AKAN) announced a settlement agreement with former CEO Tejinder Virk. This settlement concludes disputes that began after Virk's resignation on February 3, 2023. The agreement resolves all outstanding claims and disputes, allowing both parties to focus on future endeavors. CEO Katharyn Field stated that the decision to settle is in the company's best interest, enabling them to allocate resources to strategic priorities without any distractions. The agreement includes a waiver of all claims related to Virk's employment and termination.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
none
-
Rhea-AI Summary

Akanda Corp. announces plans to capitalize on the pending landmark change in US drug policy to reschedule cannabis under the Controlled Substances Act, potentially leading to significant market opportunities. The company aims to become a leader in consolidating US-based operators, following the DEA's proposal to reclassify cannabis as a Schedule III substance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.96%
Tags
management
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
AI
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.83%
Tags
none

FAQ

What is the current stock price of AKANDA (AKAN)?

The current stock price of AKANDA (AKAN) is $1.26 as of May 23, 2025.

What is the market cap of AKANDA (AKAN)?

The market cap of AKANDA (AKAN) is approximately 2.7M.
AKANDA CORP

Nasdaq:AKAN

AKAN Rankings

AKAN Stock Data

2.66M
2.26M
1.65%
1.35%
3.08%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
New Romney